Research suggests a potential topical treatment for common skin cancers, squamous cell and basal cell carcinoma Findings will be presented at 2026 RNA Therapeutics Symposium June 24-26 SAN ANTONIO, Texas – June 22, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, will present preclinical findings […]
SAN ANTONIO, Texas – June 18, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced the closing of its previously announced public offering of securities as described below for aggregate gross proceeds […]
SAN ANTONIO, Texas – June 17, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced that it has priced a Public Offering of securities as described below for aggregate gross proceeds to […]
Expert panel will share real-world case studies to demonstrate how mobile CT screening, noninvasive CyPath® Lung testing, and comprehensive functional lung imaging can reduce cost while improving access, early detection and outcomes for veterans National Association of Veterans’ Research and Education Foundations (NAVREF) to host July 21 webinar Register here SAN ANTONIO, Texas – June […]
Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices CyPath® Lung has demonstrated the ability to aid in the detection of early-stage lung cancer and support surveillance of cancer survivors for recurrence SAN ANTONIO, Texas – June 2, 2026 – bioAffinity Technologies, Inc. […]
Strong intellectual property portfolio helps build shareholder value Patent strategy protects CyPath® Lung’s flow cytometry-driven diagnostic approach in international markets SAN ANTONIO, TX – May 27, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced […]